louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07012668: Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
Official title: Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neuro-co-cardiological Diseases
Post-cardiac Surgery Cerebrovascular Diseases
Vascular Lesion
Keywords: Neuro-co-cardiological diseases
Post-cardiac surgery Cerebrovascular diseases
Simultaneous treatment
Staged treatment
Conservative treatment
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases

Brief summary: The objective of this observational cohort study is to evaluate the clinical outcomes of various treatment strategies for cerebrovascular and cardiovascular diseases. Furthermore, it aims to investigate the factors that influence adverse outcomes from these treatments.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years;
2. Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases.

Exclusion Criteria:

1. The expected survival is less than 1 years;
2. Simultaneously merge other serious diseases;

Primary outcomes:
measure: Modified Rankin Scale Score
timeFrame: 90±7 days
Secondary outcomes:
measure: Modified Rankin Scale Score
timeFrame: 7±1 days or the day discharged
measure: Modified Rankin Scale Score
timeFrame: 365±30 days
measure: Perioperative complication rate
timeFrame: 30±7 days
measure: Rate of cardiovascular and cerebrovascular events
timeFrame: 90±7 days
measure: Rate of cardiovascular and cerebrovascular events
timeFrame: 365±30 days
measure: Short-term complications
timeFrame: 90±7 days
measure: Long-term complications
timeFrame: 365±30 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
Study officials:
References:
Clinical trial NCT06457568: Validation Study of CONTEC08C Electronic Sphygmomanometer
Official title: Validation of the CONTEC08C Oscillometric Blood Pressure Monitor in General Population According to the AAMI/ESH/ISO Universal Standard (ISO 81060-2:2018)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Blood Pressure
Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor class: OTHER
First posted: 2024-06-13
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Maximum age (years): 79
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to assess the accuracy of the CONTEC08C automated oscillometric upper-arm sphygmomanometer in the general population for clinical use according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension /International Organization for Standardization (AAMI/ESH/ISO) Universal Standard (ISO 81060-2:2018).


Eligibility criteria: Inclusion Criteria:

* Subjects aged 12 to 79 years
* Subjects voluntarily participate in the clinical trial and sign the informed consent.

Exclusion Criteria:

* Subjects with cardiac arrhythmias;
* Pregnancy;
* Poor quality Korotkoff sounds;
* Subject with an arm injury incompatible with the use of a cuff-based sphygmomanometer;
* Other conditions that the investigator considers ineligible for clinical trial.

Primary outcomes:
measure: Blood pressure measurement data
timeFrame: 30mintues
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese Academy of Medical Sciences，Fuwai Hospital
state: Beijing
Study officials:
affiliation: Chinese Academy of Medical Sciences, Fuwai Hospital
name: Ying Lou, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05803668: Incidence of Cholelithiasis After Bariatric Surgery in Sohag University Hospital
Official title: Incidence of Cholelithiasis After Bariatric Surgery in Sohag University Hospital
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Cholelithiasis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-04-07
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients underwent Bariatric Surgery

Brief summary: To study the incidence and predictors of developing symptomatic gallstone disease following bariatric surgery.

Detailed description: To study the incidence and predictors of developing symptomatic gallstone disease following bariatric surgery.

A retrospective study with prospective collective data will be conducted including all patients underwent bariatric surgery in general surgical department, Sohag University between January 2015 and December 2022 who did not have gallstones in the preoperative abdominal ultrasound examinations.

Medical records will be reviewed. Demographic data such as age, gender, BMI, comorbidities as ( DM, hypertension and hyperlipidemia ) and time elapsed between the surgery to post-surgery US examination. The findings of the US examinations will be collected and analyzed. Data will be analyzed to obtain descriptive and inferential statistics.

Eligibility criteria: Inclusion Criteria:

* All adult patients underwent bariatric surgery with minimum postoperative follow up period of one year duration will be included in the study.

Exclusion Criteria:

* Patients who had cholecystectomy during the bariatric surgery.
* Pediatric age.

Primary outcomes:
measure: Number of patients who develop gall bladder stones after bariatric surgery
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
References:
Clinical trial NCT00241072: Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
Official title: A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Impaired Glucose Tolerance
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-10-18
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.


Eligibility criteria: Inclusion Criteria:

history or presenting hypertension Elevated fasting blood glucose levels -

Exclusion Criteria:

Pregnancy potential Diabetes mellitus

Other criteria apply

-

Primary outcomes:
measure: Change from baseline insulin sensitivity after 24 weeks
Secondary outcomes:
measure: Change from baseline in the function of cells that line blood vessels after 24 weeks
measure: Change from baseline in markers of vascular inflammation after 24 weeks
measure: Adverse events and serious adverse events at each study visit for 24 weeks
measure: Hematology, blood chemistries, and urine measurements for up to 24 weeks
measure: Vital signs and physical examinations for up to 24 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT06317272: BReath Hold TecHniquEs for Radiotherapy of Esophageal Carcinoma
Official title: BReath hOld TecHniquEs for Radiotherapy of Esophageal Carcinoma; a Feasibility Study - Part 1
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Esophageal Cancer
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
First posted: 2024-03-19
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The participating patients will undergo weekly (during radiotherapy treatment) 2 CTs in DIBH; one using ABC and one using voluntary coaching (VC).
Primary purpose: TREATMENT

Brief summary: The main objective of the first part of the study is to determine the most optimal method for DIBH (active breathing control vs voluntary coached) and its reproducibility. Based on these findings, one of these methods will be selected for part 2 of this study.


Eligibility criteria: Inclusion Criteria:

* Histologically proven esophageal cancer of the mid or distal esophagus
* Scheduled for external-beam photon radiotherapy with curative intention.
* WHO 0-2.
* Age \>= 18 years
* Written informed consent.

Exclusion Criteria:

* Serious respiratory distress
* Contra-indication for fiducial marker placement
* Noncompliance with any of the inclusion criteria

Primary outcomes:
measure: Feasibility DIBH
timeFrame: Week 1, 2, 3, 4, 5 during radiotherapy
measure: Reproducibility DIBH
timeFrame: Week 1, 2, 3, 4, 5 during radiotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: UMC Groningen
Study officials:
affiliation: UMC Groningen
name: C.T. Muijs, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04688268: Dose for Deep Neuromuscular Blockade Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade
Official title: Find Out the Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Laparoscopic Surgery
Keywords: laparoscopic surgery
deep neuromuscular blockade
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2020-12-29
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo laparoscopic surgery for at least 2 hours under general anesthesia.

Brief summary: Find out the deciding factor(total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) of neuromuscular blocker dose for deep neuromuscular blockade.

Detailed description: Before the surgery, total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index were measured by height and weight and skeletal muscle mass and body fat were measured by Bioelectrical impedance analysis (InbodyH20N). Find the highest correlation between the 8 factors (total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) and the amount of rocuronium administered to deep neuromuscular blockade.

Eligibility criteria: Inclusion Criteria:

* patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo laparoscopic surgery for at least 2 hours under general anesthesia

Exclusion Criteria:

* kidney disease (GFR\<60)
* allergy to study drugs
* decline participation
* side effect of propofol and remifentanil
* when anesthesia does not maintain the level of alertness (BIS) below 60 even when the anesthetic dose is increased, or when hemodynamic instability such as bradycardia and hypotension appears

Primary outcomes:
measure: the highest correlation coefficient
timeFrame: preoperative 1 days to postoperative 1 days
Secondary outcomes:
measure: onset time of rocuronium
timeFrame: preoperative 1 days to postoperative 1 days
measure: Time to deep neuromuscular blockade
timeFrame: preoperative 1 days to postoperative 1 days
measure: Recovery time
timeFrame: preoperative 1 days to postoperative 1 days
Other outcomes:
Locations:
Study officials:
References:
citation: Choi YJ, Hee Kim Y, Bae GE, Yu JH, Yoon SZ, Kang HW, Lee KS, Kim JH, Lee YS. Relationship between the muscle relaxation effect and body muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. J Int Med Res. 2019 Apr;47(4):1521-1532. doi: 10.1177/0300060518822197. Epub 2019 Feb 5.
Clinical trial NCT03225872: Biology of Osteosarcoma (BOOST) Registry and Biobank
Official title: Biology of Osteosarcoma (BOOST) Registry and Biobank
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Osteosarcoma
Keywords: Osteosarcoma
Bone cancer
Family-based study
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2017-07-21
Enrollment: 5000
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Worldwide

Brief summary: Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.

Detailed description: Summary to include:

1. Samples of saliva, blood and/or other stored material such as slides or leftover diagnostic material. If available the investigator may ask you for deciduous (baby) teeth.
2. Questionnaire information, including health history, growth and development, physical activity and family medical history information.
3. If you have been diagnosed with a osteosarcoma or another condition the investigator is interested inthe investigator will ask you release medical record information relating to diagnosis and treatment of osteosarcoma, other cancers, blood disorders, and similar conditions. If this step applies to you then you will be asked to sign a separate form.
4. You may be asked to contact your biological parents and full biological siblings to ask them about participating in the study.
5. If you agree you may be contacted in the future. You will be able to decline any future information or studies at any point.

Eligibility criteria: Inclusion Criteria:

* Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma (ICCC 9180-9200)

Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with osteosarcoma (ICCC 9180-9200)

Exclusion Criteria:

* Does not understand English.

Primary outcomes:
measure: Determine if genes can determine osteosarcoma
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Masonic Cancer Center
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Logan G. Spector, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01117272: The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women
Official title: Relationship of Metabolic Parameters, Endocrine and Prolactin Levels in Taiwan's Women With Polycystic Ovary Syndrome and Hyperprolactinemia.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Polycystic Ovary Syndrome
Keywords: PCOS
hyperprolactinemia
obesity
hyperandrogenic
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2010-05-05
Enrollment: 474
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Polycystic Ovary syndrome(PCOS)

Brief summary: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder of reproductive-age women. According to Rotterdam 2003 criteria: at least two of three criteria are met, hyperandrogenism, chronic anovulation, and polycystic ovary. PCOS will cause irregular menstrual cycle, infertility, acne, hirsutism, obesity, or/and metabolic syndrome, diabetes that may increase risk of cardiovascular disease.

Hyperprolactinaemia is also a common problem in reproductive aged women. Both hyperprolactinaemia and PCOS had endocrine disorder and irregular menstrual cycle. Investigators hope to collect clinical data from PCOS and prolactinemia patients followed in Wang Fang hospital for many years in endocrinological and metabolical aspects for comparison. Investigators at the same time would like to understand more about other similarities and differences between these two endocrinological dysfunction for future study.


Eligibility criteria: Inclusion Criteria:

* PCOM by ultrasound Diagnosis
* Anovulation, Oligo menses
* Hyperandrogenism

Exclusion Criteria:

* Women who had been diagnosed with other etiology that should be excluded in PCOS diagnosis, such as hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital adrenal hyperplastic, androgen-secreting tumor, Cushing's syndrome, disorders of uterus( such as Asherman's syndrome, Mullerian agenesis), chromosomal anomalies( such as Turner syndrome).
* Women who did not have sufficient clinical or biochemical records.
* Girls who had menarche at \<3 years of age and women who were \>40 years of age.

Primary outcomes:
measure: hyperprolactin
timeFrame: Who visited the Reproductive Endocrinology Clinic at Taipei Medical University-Wan Fang Medical Center from April 2004 to June 2007
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University WanFang Hospital
Study officials:
affiliation: Taipei Medical University WanFang Hospital
name: Ming-I Hsu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00913172: Cost and Cost-effectiveness of PTB+ Treatment in Southern Ethiopia
Official title: Improving Community Based TB Care in Southern Ethiopia Cost and Cost Effectiveness
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smear-positive TB Cases
Keywords: TB
cost
HEWs
Cost-effectiveness
treatment success rate
Lead sponsor: University of Bergen
Sponsor class: OTHER
First posted: 2009-06-04
Enrollment: 229
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study was conducted along a CRT to find out if involving HEWs improves the treatment success rate of smear-positive patients. For both treatment alternatives, smear-positive patients who were diagnosed (from September 2006 to September 2007) and started treatment were prospectively enrolled until the end of treatment. The detail of the study are given elsewhere

Brief summary: Evidences for policy making and decision related to the cost of delivering tuberculosis (TB) control is lacking in Ethiopia. The investigators aimed to determine the cost and cost-effectiveness of involving health extension workers (HEWs) in TB treatment under the community-based initiative in Ethiopia.

Detailed description: Two treatment options were compared - health facility and community DOT. In 1995, Ethiopia adopted World Health Organization (WHO) recommended DOTS strategy for TB control. The treatment regimen for new smear-positive patients includes two months of ethambutol, rifampicin, isoniazid and pyrazinamide followed by six months of ethambutol and isoniazid. For children the continuation phase treatment was replaced by four months of rifampicin and isoniazid. Follow up sputum examinations were conducted at the end of 2, 5 and 7 months treatment.

Eligibility criteria: Inclusion Criteria:

* Pulmonary tuberculosis suspects of any age and sex

Exclusion Criteria:

* Healthy individuals or non tuberculosis patients

Primary outcomes:
measure: cost per successfully treated smear-positive case
timeFrame: September 2006 to April 2008
Secondary outcomes:
Other outcomes:
Locations:
city: Yirgalem
country: Ethiopia
facility: YAHC
state: Snnpr
Study officials:
affiliation: UoB, RHB
name: Daniel G Datiko, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: UoB
name: Bernt Lindtjorn, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Datiko DG, Lindtjorn B. Cost and cost-effectiveness of smear-positive tuberculosis treatment by Health Extension Workers in Southern Ethiopia: a community randomized trial. PLoS One. 2010 Feb 17;5(2):e9158. doi: 10.1371/journal.pone.0009158.
Clinical trial NCT06798272: Monitoring of Hydration Status in Chronic Hemodialysis Patients
Official title: Measurement of Skinfold Thickness in Subscapular Area to Monitor Hydration Status in Chronic Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodialysis
Kidney Failure
Overhydration
Keywords: hemodialysis
water-electrolyte balance
dry body mass
skinfold thickness
Lead sponsor: Medical University of Lodz
Sponsor class: OTHER
First posted: 2025-01-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background Maintaining fluid balance is one of major challenges of the dialysis therapy. It includes, in particular, the management of "dry body mass". We postulated that simple measurement of subscapular skinfold thickness before and after hemodialysis could help monitor hydration status in chronic dialysis patients.

Aim of the study The aim of the study was to compare the conventional methods of monitoring hydration status during hemodialysis with an assessment of skin fold thickness.

Materials and Methods 50 participants (21 F, 29 M; age 60 ±15 years) were enrolled. Directly before the hemodialysis session the following parameters were measured: body composition with bioimpedance spectroscopy, skinfold thickness in subscapular area with standardized caliper and blood tests: blood count, urea, n-terminal pro B-type natriuretic peptide (nt-proBNP) and pro-adrenomedullin (pro-ADM). The procedures were repeated at the end of three consecutive hemodialysis sessions.


Eligibility criteria: Inclusion Criteria:

* chronic hemodialysis for at least 3 months

Exclusion Criteria:

* severe mental disabilities, poor compliance, any acute infection, instability of the cardiovascular hemodynamic condition

Primary outcomes:
measure: changes in overhydration
timeFrame: From enrollment to one week
Secondary outcomes:
Other outcomes:
Locations:
city: Lodz
country: Poland
facility: Central University Hospital
Study officials:
References: